secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001558370-25-011134
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar licenses three novel peptides from Anji for up to $453M total
-----------------------------------------------------------------------

- Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.
- First asset: endogenous peptide suppressing multiple cancer types; second: novel peptide-docetaxel conjugate; third: topical VEGFR eye drop for wet AMD.
- Upfront $6M ($0.75M earnest + $5.25M), development milestones up to $42M, sales milestones up to $225M, royalties capped at $60M per product.
- Anji receives non-exclusive license outside territory; pays Amphastar low single-digit royalties on certain net sales.
- Term: 10 years from first commercial sale per product; Amphastar can extend up to additional 10 years or patent expiry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/0001558370-25-011134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000155837025011134/amph-20250808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer